The Technical Analyst
Achilles Therapeutics plc [ACHL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Achilles Therapeutics plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.26% $0.781
America/New_York / 24 apr 2024 @ 13:28
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 32.09 mill |
| EPS: | -1.740 |
| P/E: | -0.450 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 41.08 mill |
| Avg Daily Volume: | 0.793 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.450 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -0.450 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.655 - 0.907 ( +/- 16.13%) |
| ATR Model: 14 days |
Forecast:
15:08 - $0.789
Live Trading Signals (every 1 min)
Forecast
1: 13:38 - $0.788
Forecast 2: 14:28 - $0.789
Forecast 3: 15:08 - $0.789
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.781 (-0.26% ) |
| Volume | 0.0621 mill |
| Avg. Vol. | 0.793 mill |
| % of Avg. Vol | 7.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACHL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACHL
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Latest Press Releases
2024-04-04 06:45:00 - Press Release
Achilles Therapeutics Reports Fourth Quarter And Year-end 2023 Financial Results And Recent Business Highlights
– provided interim phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma – – improved velos™ manufacturing process delivering higher cnet doses – – protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2h 2024 – – strong cash position of $131.5 million supports operations through 2025 – london, april 04, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended december 31, 2023, and recent business highlights...
2024-04-04 06:30:00 - Press Release
Achilles Therapeutics Provides Interim Phase I/iia Update On Clonal Neoantigen Reactive T Cells In Advanced Nsclc And Melanoma Including First Patients Dosed With Enhanced Host Conditioning
– improved velos™ manufacturing process delivering higher cnet doses – – protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2h 2024 – – first three patients dosed in chiron and thetis with enhanced host chemo-conditioning, along with il-2 aligned to standard til therapy, show improved cnet persistence and engraftment – london, april 04, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim phase i/iia data on the use of clonal neoantigen reactive t cells (cnet) from the chiron study in advanced unresectable or metastatic non-small cell lung cancer (nsclc) and the thetis study in recurrent or metastatic malignant melanoma...
2024-02-05 07:00:00 - Press Release
Achilles Therapeutics To Present At The 10th Annual Immuno-oncology 360 Conference
London, feb. 05, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the company will be presenting at the following conference:
2023-12-18 07:00:00 - Press Release
Achilles Therapeutics Announces Publication Of Nature Cancer ‘comment' On Strategy For Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
2023-11-13 16:30:00 - Press Release
Achilles Therapeutics Reports Third Quarter 2023 Financial Results And Recent Highlights
– on track to dose 15-20 patients with higher dose cnet by year-end 2023 – – clinical and translational science data update from the ongoing phase i/iia trials in nsclc and melanoma expected in q1 2024 with additional data available in mid-2024 – – strong cash position of $140 million supports operations through 2025 – london, nov. 13, 2023 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended september 30, 2023, and recent business highlights. “we are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology.
Latest News
2024-02-05 07:00:00 - GlobeNewsWire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:
2023-09-22 11:16:53 - Zacks Investment Research
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.
2023-06-12 08:00:00 - GlobeNewsWire
Achilles Therapeutics to Present at Upcoming Conferences
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June:
2023-05-21 10:03:52 - InvestorPlace
3 Stocks With 1,000% Upside Potential
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.
2023-02-02 11:18:40 - Zacks Investment Research
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.
2022-12-20 08:30:00 - GlobeNewsWire
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel in San Francisco, California.
2022-12-18 07:14:29 - Seeking Alpha
Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket
ACHL has about $4.40 of cash per share on hand, yet it trades below $1. I believe that recent selling is due to tax loss sellers needing to recognize capital loss before the end of the year, and hence their selling is indiscriminate.
2022-11-30 18:05:00 - GlobeNewsWire
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -
2022-11-01 13:34:20 - Zacks Investment Research
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock
Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-05-03 08:00:00 - GlobeNewsWire
Achilles Therapeutics to Present at Upcoming Conferences
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in May.